tiprankstipranks
Advertisement
Advertisement

SPRY Stock Latest News

ARS Pharmaceuticals initiated with an Outperform at Northland
The FlyARS Pharmaceuticals initiated with an Outperform at Northland
4d ago
SPRY
Northland starts disruptor ARS Pharmaceuticals with an Outperform
PremiumThe Fly
Northland starts disruptor ARS Pharmaceuticals with an Outperform
4d ago
SPRY
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
PremiumCompany Announcements
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
10d ago
SPRY
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
PremiumThe Fly
ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
17d ago
SPRY
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
PremiumTipRanks Newswire
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
28d ago
CTMX
NSRX
Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
PremiumThe FlyMidday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
1M ago
MU
VZ
ARS Pharmaceuticals Reports 2025 Results and neffy Growth
Premium
Company Announcements
ARS Pharmaceuticals Reports 2025 Results and neffy Growth
1M ago
8K
SPRY
ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)
Premium
The Fly
ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)
1M ago
SPRY
ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
PremiumThe Fly
ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
2M ago
SPRY
ARS Pharmaceuticals announces California eligible for neffyinSchools program
PremiumThe Fly
ARS Pharmaceuticals announces California eligible for neffyinSchools program
3M ago
SPRY
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
PremiumRatings
ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
3M ago
SPRY
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
PremiumRatings
Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
3M ago
SPRY
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
PremiumThe FlyARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
3M ago
AQST
SPRY
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
Premium
The Fly
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
3M ago
SPRY
ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating
Premium
Ratings
ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating
5M ago
SPRY
ARS Pharmaceuticals management to meet with Oppenheimer
PremiumThe Fly
ARS Pharmaceuticals management to meet with Oppenheimer
5M ago
SPRY
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
PremiumThe Fly
ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
5M ago
SPRY
ARS Pharmaceuticals Reports Strong Q3 2025 Growth
PremiumCompany Announcements
ARS Pharmaceuticals Reports Strong Q3 2025 Growth
5M ago
SPRY
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
5M ago
SPRY
Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
PremiumRatingsPromising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
5M ago
SPRY
ARS Pharmaceuticals Reports Q3 2025 Financial Results
Premium
Company Announcements
ARS Pharmaceuticals Reports Q3 2025 Financial Results
5M ago
8K
SPRY
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
Premium
The Fly
ARS Pharmaceuticals reports Q3 EPS (52c), consensus (49c)
5M ago
SPRY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >